tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Zymeworks announces FDA clearance of IND application for ZW251

Zymeworks (ZYME) announced the U.S. FDA has cleared the investigational new drug application for ZW251, a novel glypican-3-targeted ADC incorporating the company’s proprietary topoisomerase 1 inhibitor payload, ZD06519, for the treatment of HCC. The company plans to commence Phase 1 clinical studies for ZW251 in 2025.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1